GenoMembrane is Biotechnology in Japan that focus on toxicological studies business. Founded in 2002. They cover business area such as operator, drug transporter-relate technology, kit, drug transporter analysis, a compound, interest, ABC, medical professional, useful tool, absorption, distribution, metabolism, excretion, ADME, toxicological study, drug development, drug resistance mechanism, anti-cancer drug.
2002
( 22 years old in 2024 )
Toxicological Studies
-
3F Ishikawa EMC Laboratory Building
2-3-18 Namamugi, Tsurumi-ku, Kanagawa
Yokohama, 230-0052
Japan
Private
operatordrug transporter-relate technologykitdrug transporter analysisa compoundinterestABCmedical professionaluseful toolabsorptiondistributionmetabolismexcretionADMEtoxicological studydrug developmentdrug resistance mechanismanti-cancer drug
* We use standard office opening hours in near GenoMembrane's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
GenoMembrane is Biotechnology business from Japan that founded in 2002 (22 years old in 2024), GenoMembrane business is focusing on Toxicological Studies.
GenoMembrane headquarter office and corporate office address is located in 3F Ishikawa EMC Laboratory Building 2-3-18 Namamugi, Tsurumi-ku, Kanagawa Yokohama, 230-0052 Japan.
GenoMembrane was founded in Japan.
In 2024, GenoMembrane is currently focus on toxicological studies sector.
Above is snippet of Google Trends for "toxicological studies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with GenoMembrane, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
